Form 483

Somatics, LLC Form 483, 2012-01-25

FDA issued a Form 483 to Somatics, LLC on 2012-01-25 with 11 public-safe observations.

483· Form 483 issued11 observations

Somatics, LLC · Venice, United States · Issued January 25, 2012

Overview

  • 11 public-safe observations are available for this inspection.
  • 10 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

25 Jan 2012
21 CFR 803.17(a)(1)

Lack of System for Event Evaluations

Cited by Rafael Padilla

25 Jan 2012
21 CFR 820.30(g)

Design validation - documentation

Cited by Rafael Padilla

25 Jan 2012
21 CFR 820.30(g)

Design validation- Lack of or inadequate procedures

Cited by Rafael Padilla

25 Jan 2012
21 CFR 820.50(b)

Supplier notification of changes

Cited by Rafael Padilla

25 Jan 2012
21 CFR 820.80(b)

Lack of or inadequate receiving acceptance procedures

Cited by Rafael Padilla

Inspected site

SLSomatics, LLCVenice, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 820.30(g)Cited across public-safe Form 483 observations2x
21 CFR 803.17(a)(1)Cited across public-safe Form 483 observations1x
21 CFR 820.198(a)Cited across public-safe Form 483 observations1x
21 CFR 820.198(e)Cited across public-safe Form 483 observations1x
21 CFR 820.250(a)Cited across public-safe Form 483 observations1x
21 CFR 820.250(b)Cited across public-safe Form 483 observations1x
21 CFR 820.50(b)Cited across public-safe Form 483 observations1x
21 CFR 820.80(b)Cited across public-safe Form 483 observations1x
21 CFR 820.80(e)Cited across public-safe Form 483 observations1x
21 CFR 820.90(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 11 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere